메뉴 건너뛰기
Endocrine Practice
Volumn 17, Issue 4, 2011, Pages 658-659
Rapid weight loss and decrease in hemoglobin A 1c after treatment with topiramate in a patient with status epilepticus
Author keywords

[No Author keywords available]
Indexed keywords

ETIRACETAM; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; TOPIRAMATE;
EID: 84860413132     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: None     Document Type: Letter
Times cited : (1)
References (5)
  • 1
    • 0345690127 scopus 로고    scopus 로고
    • Levetiracetam does not alter body weight: Analysis of randomized, controlled clinical trials
    • DOI 10.1016/j.eplepsyres.2003.08.009
    • Gidal BE, Sheth RD, Magnus L, Herbeuval AF. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res. 2003;56: 121-126. (Pubitemid 37464925)
    • (2003) Epilepsy Research , vol.56 , Issue.2-3 , pp. 121-126
    • Gidal, B.E.1    Sheth, R.D.2    Magnus, L.3    Herbeuval, A.-F.4
  • 2
    • 33845750696 scopus 로고    scopus 로고
    • Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study
    • DOI 10.1038/sj.ijo.0803382, PII 0803382
    • Toplak H, Hamann A, Moore R, et al. Effcacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond). 2007;31:138-146. (Pubitemid 46006027)
    • (2007) International Journal of Obesity , vol.31 , Issue.1 , pp. 138-146
    • Toplak, H.1    Hamann, A.2    Moore, R.3    Masson, E.4    Gorska, M.5    Vercruysse, F.6    Sun, X.7    Fitchet, M.8
  • 3
    • 34250842579 scopus 로고    scopus 로고
    • Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: Randomized double-blind placebo-controlled trial
    • DOI 10.1038/sj.ijo.0803548, PII 0803548
    • Eliasson B, Gudbjörnsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes (Lond). 2007;31:1140-1147. (Pubitemid 46987760)
    • (2007) International Journal of Obesity , vol.31 , Issue.7 , pp. 1140-1147
    • Eliasson, B.1    Gudbjornsdottir, S.2    Cederholm, J.3    Liang, Y.4    Vercruysse, F.5    Smith, U.6
  • 4
    • 34249899669 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients
    • DOI 10.2337/dc06-2001
    • Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A (OBD-202 Study Group). A randomized, double-blind, placebo-controlled, multicenter study to assess the effcacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007;30:1480-1486. (Pubitemid 46871158)
    • (2007) Diabetes Care , vol.30 , Issue.6 , pp. 1480-1486
    • Rosenstock, J.1    Hollander, P.2    Gadde, K.M.3    Sun, X.4    Strauss, R.5    Leung, A.6
  • 5
    • 33947668881 scopus 로고    scopus 로고
    • Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes
    • DOI 10.1111/j.1463-1326.2006.00618.x
    • Stenlöf K, Rössner S, Vercruysse F, Kumar A, Fitchet M, Sjöström L (OBDM-003 Study Group). Topiramate in the treatment of obese subjects with drug-naïve type 2 diabetes. Diabetes Obes Metab. 2007;9:360-368. (Pubitemid 46502056)
    • (2007) Diabetes, Obesity and Metabolism , vol.9 , Issue.3 , pp. 360-368
    • Stenlof, K.1    Rossner, S.2    Vercruysse, F.3    Kumar, A.4    Fitchet, M.5    Sjostrom, L.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.